Hazal Çelik is currently the Global HTA Evidence Lead at Roche, a position they have held since September 2019. Prior to this role, they worked as a Consultant at Ingress-health and as a Pricing and Market Access Specialist at Roche. Hazal has a solid background in clinical research, having served in various positions at AbbVie and MSD Türkiye. They hold a Master of Pharmacy from Istanbul University and have completed master's degrees in Health Economics and Market Access and Biostatistics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices